Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals (CSE:AGN) reports “additional positive data” from Phase 2 Study of Ifenprodil

Dave Jackson July 28, 2022

Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

GlobeNewswire July 28, 2022

Crossing the finish line: Algernon (CSE:AGN) reaches endpoint in Phase 2a study of Ifenprodil

Dave Jackson July 22, 2022

Algernon Pharmaceuticals (CSE:AGN) achieves co-primary endpoint in its Phase 2 study of Ifenprodil

John Ballem  July 18, 2022

IIROC Trade Resumption - AGN

Canada NewsWire July 18, 2022

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

GlobeNewswire July 18, 2022

IIROC Trading Halt - AGN

Canada NewsWire July 15, 2022

Algernon Pharmaceuticals (CSE:AGN) updates its planned Phase 1 Repirinast Chronic Kidney Disease study

John Ballem  July 11, 2022

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

GlobeNewswire July 11, 2022

Algernon Pharmaceuticals (CSE:AGN) updates Phase 1 DMT human stroke study

John Ballem  July 7, 2022

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

GlobeNewswire July 7, 2022

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

GlobeNewswire July 5, 2022

Algernon Pharmaceuticals Inc. (CSE:AGN) closes public offering of units

Azuka Onwuka July 4, 2022

Algernon Pharmaceuticals Announces Closing of Public Offering of Units

GlobeNewswire July 4, 2022

Algernon Pharmaceuticals (CSE:AGN) announces pricing of public offering

John Ballem  June 27, 2022

Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

GlobeNewswire June 27, 2022

Algernon Pharmaceuticals (CSE:AGN) receives patent for Ifenprodil

John Ballem  June 22, 2022

Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

GlobeNewswire June 22, 2022

Algernon (CSE:AGN) receives requests for ongoing supply of Ifenprodil from study participants

Azuka Onwuka June 21, 2022

Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended

GlobeNewswire June 21, 2022